TG Therapeutics Approaches Its First Test of Whether Last Quarter's Miss Was Noise or Pattern

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

TG Therapeutics reports before market open, meaning Day 0 captures the first full trading session reaction while Day +1 reflects follow-through momentum.

Historical price action around earnings shows significant volatility, with an average absolute Day 0 move of 12.28% and Day 0 range of 13.79%. The most recent release on May 6, 2026, triggered a +16.26% surge despite the earnings miss, suggesting the market focused on other positive factors such as revenue beats or forward guidance. However, the pattern has been inconsistent—prior releases in August 2025 and May 2025 both saw sharp declines of -17.99% and -13.26% respectively on Day 0.

The Day +1 follow-through has been more muted, averaging 3.33% with a 7.34% range, indicating most of the price discovery occurs in the immediate reaction session. Investors should prepare for a potential double-digit percentage move in either direction based on not just the headline EPS result, but also revenue performance, guidance updates, and commentary on the commercial trajectory. The wide historical range suggests options strategies may be appropriate for those seeking to manage risk around the announcement.

Part 2.2: Options Market Expected Move

The options market is pricing an 11.64% expected move for the August 21 expiration, slightly below the 12.28% average historical Day 0 move but well within the typical range. This suggests options traders are anticipating meaningful volatility but not an outsized reaction compared to recent history, despite the elevated earnings estimate and uncertain track record.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on TG Therapeutics with an average recommendation of 4.22 out of 5.00, reflecting a Strong Buy consensus. The breakdown shows 6 Strong Buy ratings, 2 Hold ratings, and 1 Moderate Sell, with no Strong Sell recommendations among the 9 analysts covering the stock. This represents unchanged sentiment from one month ago, indicating stable conviction despite recent earnings volatility.

The average price target of $63.50 implies 22.1% upside from the current price of $52.03, with a wide range spanning from a low target of $20.00 to a high of $86.00. The $66.00 spread between high and low targets reflects divergent views on the company's commercial execution and path to sustained profitability. The most bullish analysts see potential for 65% upside if BRIUMVI adoption accelerates and the company demonstrates operating leverage, while the bearish outlier at $20.00 suggests concerns about competitive pressures or execution risk.

The maintained Strong Buy consensus despite three earnings misses in the last four quarters indicates analysts are looking past near-term volatility and focusing on the longer-term opportunity. The 2027 estimate of $2.94 per share—more than double the 2026 forecast—suggests the analyst community expects meaningful earnings growth as the commercial infrastructure matures and the company achieves scale.

Part 4: Technical Picture

The Barchart Technical Opinion stands at 80% Buy, down from 100% Buy one week ago and one month ago, indicating some recent deterioration in technical momentum heading into the earnings release. The stock is currently trading at $52.03, positioned below its 5-day ($53.93), 10-day ($54.18), and 20-day ($55.24) moving averages, but above its 50-day ($49.92), 100-day ($42.33), and 200-day ($36.68) moving averages.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum has weakened from recent highs, with the stock pulling back from its 20-day moving average
• Medium-term (100% Buy): Strong buy signal indicates the intermediate trend remains firmly positive, supported by the stock's position well above the 50-day moving average
• Long-term (100% Buy): Strong buy signal reflects robust longer-term uptrend, with the stock trading 42% above its 200-day moving average

Trend Characteristics: The Strong strength combined with Average direction suggests a well-established uptrend that has entered a consolidation phase, creating a neutral-to-slightly-cautious backdrop for the earnings event.

The technical setup presents a mixed picture heading into earnings. While the longer-term trend remains constructive with the stock holding well above its 200-day moving average at $36.68, the recent pullback below short-term moving averages and weakening near-term momentum signal caution. The stock has given back ground from recent highs near $55, creating overhead resistance in the $53-$55 zone. Support appears solid at the 50-day moving average around $50, which has contained recent weakness. Given the 11.64% expected move and historical 12.28% average reaction, a break above $55 on strong results could target the $58-$60 range, while disappointment could test the $47-$50 support zone. The technical deterioration from 100% Buy to 80% Buy over the past month suggests some profit-taking ahead of the event, potentially setting up for a "sell the news" reaction even on in-line results.